Ixekizumab: an alternative for HIV-positive psoriasis patients.

IF 2.1 4区医学 Q3 INFECTIOUS DISEASES

AIDS Research and Therapy Pub Date : 2024-11-28 DOI:10.1186/s12981-024-00675-8

Fanghua Liu, Zhou Liu, Rongming Yang, Dandan Huang, Yongzhi Han

引用次数: 0

Abstract

Psoriasis is a recurrent and protracted inflammatory disease. Generalized erythema, plaques, and silvery scales on the surface mainly characterize its skin lesions. Biologics bring new hope to psoriasis patients. However, HIV infection is a major concern before receiving biologics. Here, we present a case of the efficacy and safety of Ixekizumab, an interleukin 17 inhibitor, in the treatment of psoriasis patients living with HIV (PPLHIV).

查看原文本刊更多论文

Ixekizumab：HIV 阳性银屑病患者的另一种选择。

银屑病是一种反复发作、久治不愈的炎症性疾病。皮损以泛发性红斑、斑块和表面银白色鳞屑为主。生物制剂为银屑病患者带来了新希望。然而，在接受生物制剂治疗之前，艾滋病病毒感染是一个主要问题。在此，我们介绍了白细胞介素 17 抑制剂 Ixekizumab 治疗感染艾滋病毒的银屑病患者（PPLHIV）的有效性和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

AIDS Research and Therapy INFECTIOUS DISEASES-

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

16 weeks

期刊介绍： AIDS Research and Therapy publishes articles on basic science, translational, clinical, social, epidemiological, behavioral and educational sciences articles focused on the treatment and prevention of HIV/AIDS, and the search for the cure. The Journal publishes articles on novel and developing treatment strategies for AIDS as well as on the outcomes of established treatment strategies. Original research articles on animal models that form an essential part of the AIDS treatment research are also considered